

7 Literaturverzeichnis

1. Aggarwal A, Malkovska V, Catlett JP, Alcorn K: Recombinant activated factor VII (rFVIIa) as salvage treatment for intractable hemorrhage. *Thrombosis J* 2004; 2:9
2. Al Douri M, Shafi T, Al Khudairi D, Al Bokhari E: Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven®) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. *Blood Coag Fibrinol* 2000; 11 (Suppl 1): 121-127
3. Allen GA, Hoffman M, Roberts HR, Monroe DM: Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia. *Br J Haematol* 2006; 134(3):314-319
4. Barletta JF, Ahrens CL, Tyburski JG, Wilson RF: A review of recombinant factor VII for refractory bleeding in nonhemophilic trauma patients. *J Trauma* 2005; 58:646-651
5. Basso IN, Keeling D: Myocardial infarction following recombinant activated factor VII in a patient with type 2A von Willebrand disease. *Blood Coagul Fibrinolysis* 2004; 15(6):503-504
6. Bauer KA: Treatment of factor VII deficiency with recombinant factor VIIa. *Haemostasis* 1996; 26:155-158
7. Berkner K, Busy S, Davie E: Isolation and expression of cDNAs encoding for human factor VII. *Cold Spring Harb Symp Quant Biol* 1986; 51:531-541
8. Bernstein DE, Jeffers L, Erhardtsen E: Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: A preliminary study. *Gastroenterology* 1997; 113:1930-1937
9. Berntorp E, Stigendal L, Lethagen S: NovoSeven in warfarin treated patients. *Blood coagul fibrinolysis* 2000; 11(Suppl1):113-115
10. Bishop CV, Renwick WE, Hogan C, Haeusler M: Recombinant Activated Factor VII: Treating Postoperative Hemorrhage in Cardiac Surgery. *J Ann Thorac Surg* 2006; 81:875-879
11. Boffard KD, Riou B, Warren B, Iau Tsau Choong P: Recombinant Factor VIIa as Adjunctive Therapy for Bleeding Control in Severely Injured Trauma Patients: Two Parallel randomized, Placebo-Controlled, Double-Blind Clinical Trials. *J Trauma* 2005; 59: 8-18
12. Boffard KD, Warren B, Iau Tsau Choong P: Decreased transfusion utilization and improved outcome associated with the use of recombinant factor VIIa as an adjunct in trauma. *J Trauma* 2004; 57:451
13. Bosch J, Thabut D, Bendtsen F, D'Amico G: Recombinant Factor VIIa for Upper Gastrointestinal Bleeding in Patients With Cirrhosis: A Randomized, Double-Blind Trial. *Gastroenterology* 2004; 127:1123-1130
14. Bui JD, Despotis GD, Trulock EP, Patterson GA, Goodnough LT: Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII. *J Thorac Cardiovasc Surg* 2002; 124: 852-854

15. Bundesärztekammer, Arbeitsgemeinschaft der deutschen Ärztekammern: Leitlinien zur Therapie mit Blutkomponenten und Plasmabestandteilen. 3. überarbeitete und erweiterte Auflage. Deutscher Ärzte-Verlag, Köln 2003: 1-170
16. Clark AD., Gordon WC: `Last-ditch`use of recombinant factor VIIa in patients with massive haemorrhage is ineffective. *Vox Sang* 2004; 86: 120-124
17. Chung JH, Gikakis N, Rao AK, Drake TA: Pericardial blood activated the extrinsic coagulation pathway during clinical cardiopulmonary bypass. *Circulation* 1996; 93:2014-2018
18. Dacey LJ, Munoz JJ: Reexploration for hemorrhage following coronary artery bypass grafting. *Arch Surg* 1998; 133: 442-447
19. Dempfle CE: Gerinnungsstörungen bei Sepsis. *Hämostaseologie* 2005; 25:183-189
20. de Pont AC, Bakhtiari K, Hutten BA, de Jonge E: Endotoxaemia induces resistance to activated protein C in healthy humans. *Br J Haematol* 2006; 134:213-219
21. Despotis GJ, Filos KS, Zoys TN, Hogue CW Jr, Spitznagel E, Lappas DG: Factors Associated with Excessive Blood Loss and Hemostatic Transfusion Requirements: A Multivariate Analysis in Cardiac Surgical Patients. *Anesth Analg* 1996; 82:13-21
22. Despotis GJ, Levine V, Saleem R, Spitznagel E, Joist HJ: Use of point-of-care test in identification of patients who can benefit from desmopressin during cardiac surgery: a randomized controlled trial. *Lancet* 1999; 354(9173): 106-110
23. Despotis GJ, Avidan MS: Mechanisms and Attenuation of Hemostatic Activation During Extracorporeal Circulation. *Ann Thorac Surg* 2001; 72:1821-1831
24. Despotis G, Avidan M, Lublin DM: Off-Label Use of Recombinant Factor VIIa Concentrates After Cardiac Surgery. *Ann Thorac Surg* 2005; 80:3-5
25. DiDomenico RJ, Massad MG, Kpodonu J, Navarro RA.: Use of Recombinant Activated Factor VII for Bleeding Following Operations Requiring Cardiopulmonary Bypass. *Chest* 2005; 127:1828-1835
26. Dietrich W: Cardiac surgery and the coagulation system. *Curr Opin Anaesthesiol* 2000; 13:27-34
27. Dietrich W, Spannagel M: Caveat Against the Use of Activated Recombinant Factor VII for Intractable Bleeding in Cardiac Surgery. *Letters to the Editor. Anaesth Analg* 2002; 94:1369-1370
28. Diprose P, Herbertson MJ, O`Shaughnessy D, Deakin CD, Gill RS: Reducing allogeneic transfusion in cardiac surgery: a randomized double-blind placebo-controlled trial of antifibrinolytic therapies used in addition to intra-operative cell salvage. *Br J Anaesth* 2005; 94:271-278
29. Diprose P, Herbertson MJ, O`Shaughnessy D, Gill RS: Activated recombinant factor VII after cardiopulmonary bypass reduced allogenic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. *Br J Anaesth* 2005; 95: 596-602

30. Ejlersen E, Melsen T, Ingerslev J: Recombinant activated factor VII (rFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices. *Scand J Gastroenterol* 2001; 36:1081-1085
31. Engoren ML, Habib RH, Zacharias A, Schwann TA: Effect of blood transfusion on long-term survival after cardiac operation. *Ann Thorac Surg* 2002; 74:1180-1186
32. Ernofsson M, Thelin S, Siegbahn A: Monocyte tissue factor expression, cell activation and thrombinformation during cardiopulmonary bypass: a clinical study. *J Thorac Cardiovasc Surg* 1997; 113(3):576-584
33. Farrugia A: Assessing Efficacy and Therapeutic Claims in Emerging Indications for recombinant factor VIIa: Regulatory Perspectives. *Semin Hematol* 2006; 43(1):64-69
34. Ferraris VA, Ferraris SP, Joseph O, Wehner P: Aspirin and postoperativ bleeding after coronary artery bypass grafting. *Ann Surg* 2002; 235:820-827
35. Fink R, Al-Obaidi M, Grewal S, Winter M: Monocyte activation markers during cardiopulmonary bypass. *Perfusion* 2003; 18:83-86
36. Franchini M, Zaffanello M, Veneri D: Recombinant factor VIIa. An update to its clinical use. *Thromb Haemost* 2005; 93:1027-1035
37. Friedrich PW, Henny CP, Messelink EJ, Geerdink MG: Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing prostatectomy: a double-blind placebo-controlled randomised trial. *Lancet* 2003; 361:201-205
38. Friedrich PW, Levi M, Bauer KA: Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects. *Circulation* 2001; 103:2555-2559
39. Gabriel DA, Li X, Monroe DM: Recombinant human factor VIIa (rFVIIa) can activate factor IX on activated platelets. *J Thromb Haemost* 2004, 2:1816-1822
40. Gallistl S, Cvirn G, Muntean W: Recombinant factor VIIa does not induce hypercoagulability in vitro. *Thromb Haemost* 1999; 81:245-249
41. Gando S: Tissue factor in trauma and organ dysfunction. *Semin Thromb Hemost* 2006; 32(1):48-53
42. Gerotziapas GT, Chakroun T, Depasse F, Arzoglou P, Samama MM: The role of platelets and recombinant factor VII on thrombin generation, platelet activation and clot formation. *Thromb Haemost* 2004; 91:977-985
43. Goldstein DJ, Beauford R: Left Ventricular Assist Devices and Bleeding: Adding Insult to Injury. *Ann Thorac Surg* 2003; 75:42-47
44. Goodnough LT: Risk of blood transfusion. *Crit Care Med* 2003; 31: 678-686
45. Goodnough LT, Shander A, Brecher ME: Transfusion medicine: looking to the future. *Lancet* 2003; 361(9352): 161-169
46. Goodnough LT, Lublin DM, Zhang L: Transfusion medicine service policies for recombinant factor VIIa administration. *Transfusion* 2004; 44:1325-1331

47. Grounds MR, Seebach C, Knothe C, Paluszkiwicz P, Smith TS: Use of Recombinant Activated Factor VII (Novoseven) in Trauma and Surgery: Analysis of Outcomes Reported to an International Registry. *J Intensive Care Med* 2006; 21:27-39
48. Guyatt GH, Haynes RB, Jaeschke RZ, Cook DJ, Green L: Evidence-based medicine: principles for applying the User's Guides to patient care. Evidence-Based Medicine Working Group. *JAMA* 2000; 284:1290-1296
49. Guyatt GH, Sackett DL, Cook DJ: User's guide to medical literature. III. How to use an article about therapy or prevention. A. Are the results of the study valid? Evidence-Based Medicine Working Group. *JAMA* 1993; 270:2598-2601
50. Hagen F, Gray L, O'Hara P: Characterisation of cDNA coding for human factor VII. *Proc Natl Acad Sci USA* 1986; 83:2412-2416
51. Halkos ME, Levy JH, Chen E, Reddy VS, Lattouf OM: Early Experience With Activated Recombinant factor VII for Intractable Hemorrhage After Cardiovascular Surgery. *Ann Thorac Surg* 2005; 79:1303-1306
52. Hardy JF, Perrault J, Tremblay N: The stratification of cardiac surgical procedures according to use of blood products: A retrospective analysis of 1480 cases. *Can J Anaesth* 1991; 38:511-517
53. Harrison TD, Laskosky J, Jazaeri O, Pasquale MD, Cipolle M: "Low-Dose" Recombinant Activated Factor VII Results in Less Blood and Blood Product Use in Traumatic Hemorrhage. *J Trauma* 2005; 59(1): 150-154
54. Hay CRM, Negrier C, Ludlam CA: The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: A multicentre Study. *Thromb Haemost* 1997; 78:1463-1467
55. Hedner U, Glazer S: Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. (Letter). *Lancet* 1988, ii, 1193
56. Hedner U, Kisiel W: Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. *J Clin Invest* 1983; 71: 1836-1841
57. Hedner U, Erhardtson E: Potential role for rFVIIa in transfusion medicine. *Transfusion* 2002. 42:114-124
58. Hedner U: Recombinant FVIIa. *Vox Sang* 2004; 87 Suppl:25-28
59. Hendriks HGD, van der Maaten JMAA: An Effective Treatment of Severe Intractable Bleeding After Valve Repair by One Single Dose of Activated Recombinant Factor VII. *Anesth Analg* 2001; 93:287-289
60. Hendriks HGD, Meijer K, de Wolf JT, Klompmaker IJ: Reduced transfusion requirements by recombinant factor VII in orthotopic liver transplantation: a pilot study. *Transplantation* 2001; 71:402-405
61. Henry DA, Moxey AJ, Carless PA: Anti-fibrinolytic use for minimising perioperativ allogenic blood transfusion (Cochrane review). 2001 *Cochrane Database Syst Rev*:CD001886
62. Herbertson M: Recombinant activated factor VII in cardiac surgery. *Blood Coagul Fibrinolysis* 2004. 15(spl 1) :31-32
63. Heuer L, Blumenberg D: Recombinant faktor VIIa - a new option in intractable bleeding? *Int J Int Care*, Summer 2003;
64. Hoffman M, Monroe DM: A cell based model of hemostasis. *Thromb Haemost* 2001; 88:958-965

65. Hyllner M, Houltz E, Jeppson A: Recombinant activated factor VII in the management of life-threatening bleeding in cardiac surgery. *Eur J Car Thor Surg* 2005; 1-5
66. Jeffers L, Chalasani N, Balart L: Safety and efficacy of recombinant factor VII in patient with liver disease undergoing laparoscopic liver biopsy. *Gastroenterology* 2002; 123:118-126
67. Jude B, Zawadzki C, Susen S, Corseaux D: Relevance of tissue factor in cardiovascular disease. *Arch Mal Coer Vaiss* 2005; 98(6):667-671
68. Kaplan M, Cimen S, Kut MS, Demirtas MM: Cardiac operations for patients with chronic liver disease. *Heart Surg Forum* 2002; 5:60-65
69. Karkouti K, Beattie WS, Wijeyesundera DN, Yau TM: Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis. *Transfusion* 2005; 45:26-34
70. Karkouti K, Wijeyesundera DN, Yau TM, Beattie WS: The independent association of massive blood loss with mortality in cardiac surgery. *Transfusion* 2004; 44(10):1453-1462
71. Karkouti K, Yau TM, Riazi S et al.: Determinants of complications with recombinant factor VIIa for refractory blood loss in cardiac surgery. *Can J Anesth* 2006; 53(8):802-809
72. Kastrup M, von Heymann C, Hotz H, Konertz WF, Ziemer S, Kox WJ, Spies C: Recombinant Factor VIIa after aortic valve replacement in a patient with osteogenesis imperfecta. *Ann Thorac Surg* 2002; 74:910-912
73. Kenet G, Walden R, Eldad A, Martinowitz U: Treatment of traumatic bleeding with recombinant factor VIIa. *Lancet* 1999; 354:1879
74. Kenet G, Lubetsky A, Luboshitz J: A new aproach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven®). *J Thromb Haemost* 2003; 1: 450-455
75. Key NS, Christie B, Henderson N, Nelsestven GL: Possible synergy between factor VIIa and prothrombin complex concentrate in hemophiliac therapy. *Thromb Haemost* 2002; 88:60-65
76. Klitgaard T, Tabanera y Palacois R, Boffard KD: Pharmacokinetics of recombinant activated factor VII in trauma patients with severe bleeding. *Crit Care* 2006; 10:R104
77. Knaus WA, Draper EA, Wagner DP: APACHE II: A severity of disease classification system. *Crit Care Med* 1985; 13:818-829
78. König H, Hanker-Dusel C, Eich S, Grundmann C, Seitz R: The thrombogenic agent in prothrombin complex concentrates (PCC): Identification of elevated levels of prothrombin as the major cause. *Thromb Haemost* 2003; 90(1): 16-48
79. Kristensen J, Killander A, Hippe E, Helleberg C: Clinical experience with recombinant factor VII in patients with thrombocytopenia. *Haemostasis* 1996; 26(suppl1):159-164
80. Lang T, von Depka M: Diagnostische Möglichkeiten und Grenzen der Thrombelastometrie/-graphie. *Hämostaseologie* 2006; 26(1):20-29
81. Laupacis A, Fergusson D: Drugs to Minimize Perioperative Blood loss in Cardiac Surgery: Meta-Analyses Using Perioperative Blood Transfusion As the Outcome. For The International Study of Peri-Operative Transfusion (ISPOT) Investigators. *Anesth Analg* 1997; 85(6):1258-1267

82. Levy JH, Fingerhut A, Brott T, Langbakke IH, Erhardtsen E, Porte RJ: Recombinant factor VIIa in patient with coagulopathy secondary to anticoagulant therapy, cirrhosis or severe traumatic injury: review of safety profile. *Transfusion* 2006; 46:919-933
83. Levi M; Cromheecke ME: Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. *Lancet* 1999; Vol 354: 1940-1947
84. Levi M, Peters M: Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: A systemic review. *Crit Care Med* 2005; Vol 33, No 4: 883-890
85. Lisman T, Moschatsis S, Adelmeijer J, Nieuwenhuis HK: Recombinant factor VIIa enhances deposition of platelets with congenital or acquired $\alpha_{11b}\beta_3$ deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation. *Blood* 2003; 101:1864-1870
86. Lodge JPA, Jonas S, Oussoultzoglou E, Malagò M: Recombinant Coagulation Factor VIIa in Major Liver Resection: A Randomized, Placebo-controlled, Double-blind Clinical Trial. *Anesthesiology* 2005; 102(2):269-275
87. Lodge JPA, Jonas S, Jones RM, Olausson M, Mir-Pallardo J, Soefelt S: Efficacy and Safety of Repeated Perioperative Doses of Recombinant factor VIIa in Liver Transplantation. *Liver Transpl* 2005;11(8): 973-979
88. Lusher JM, Roberts HR, Davignon G: A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. *RFVIIa Study Group. Haemophilia* 1998; 4:790-798
89. Mangano DT, Tudor IC, Dietzel C: Multicenter Study of perioperative Ischemia Research Group; Ischemia Research and Education Foundation. The Risk Associated with Aprotinin in Cardiac Surgery. *N Engl J Med* 2006; 354:353-365
90. Martinowitz U, Kenet G, Segal E: Recombinant activated factor VII for adjunctive hemorrhage control in trauma. *J Trauma* 2001; 51:431-438
91. Martinowitz U, Michaelson M: The Israeli Multidisciplinary rFVIIa Task Force: Guidelines for use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. *J Thromb Haemost* 2005; 3(4): 640-648
92. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Dringer MN: Recombinant activated factor VII for acute intracerebral hemorrhage. *N Engl J Med* 2005; 352(8): 777-785
93. Mayo A, Misgav M, Kluger Y: Recombinant activated factor VII: addition to replacement therapy in acute, uncontrolled and life-threatening bleeding. *Vox Sang* 2004; 51:431-439
94. McCall P, Story DA, Karapillai D: Audit of factor VIIa for bleeding resistant to conventional therapy following complex cardiac surgery. *Can J Anaesth* 2006; 53(9):926-933
95. McIlroy DR, Silvers AJ: Recombinant Factor VIIa for Life-Threatening Bleeding in High-Risk Cardiac Surgery Despite Full-Dose Aprotinin. *Anesth Analg* 2004; 99:27-30

96. Members of the American College of chest Physicans/ Society of Critical Care Medicine Consensus Conference Committee: American College of chest Physicans/ Society of Critical Care Medicine Consensus Conference (1992): Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. *Crit Care Med* 1992; 20: 864-874
97. Meng ZH, Wolberg AS, Monroe DM, Hoffman M: The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. *J Trauma* 2003; 55:886-891
98. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. *Lancet* 2001; 358(9281):527-533
99. Michalska-Krzanowska G, Czuprynaska M: Recombinant factor VII (activated) for haemorrhagic complications of severe sepsis treated with recombinant protein C (activated). *Acta Haematol* 2006; 116:126-130
100. Moulton MJ, Creswell LL, Mackey ME, Cox JL, Rosenbloom M: Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations. *J Thorac Cardiovasc Surg* 1996;111:1037-1046
101. Monroe DM: A possible mechanism of action of activated factor VII independent of tissue factor. *Blood Coag Fibrinolysis* 1998; 9(1):15-20
102. Munoz JJ, Birkmeyer NJO, Birkmeyer JD, O'Connor GT, Dacey LJ: Is ε-Aminocaproic Acid as Effective as Aprotinin in Reducing Bleeding With Cardiac Surgery. *Circulation* 1999; 99:81-89
103. NovoSeven[®] Fachinformation (Zusammenfassung der Merkmale des Arzneimittels), Januar 2004, Novo Nordisk A/S
104. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM: Tromboembolic Adverse Events After Use of Recombinant Human Coagulation Factor VIIa. *JAMA* 2006; 295:293-298
105. Osterud B: Tissue factor expression by monocytes: regulation and pathophysiological roles. *Blood Coagul Fibrinolysis* 1998; 9:9-14
106. Paparella D, Brister SJ, Buchanan MR: Coagulation disorders of cardiopulmonary bypass: a review. *Intensive Care Med* 2004; 30:1873-1881
107. Parr KG, Patel MA, Dekker R, Levin R: Multivariate predictors of blood product use in cardiac surgery. *J Cardiothorac Vasc Anesth* 2003; 17(2):176-181
108. Pleym H, Stenseth R, Wahba A, Bjella L, Tromsdal A, Karevold A, Dale O: Prophylactic Treatment with Desmopressin Does Not Reduce Postoperativ Bleeding after Coronary Surgery in Patients Treated with Aspirin Before Surgery. *Anesth Analg*, 2004; 98:578-584
109. Poon MC, d'Oiron R: Recombinant activated favor VII (NovoSeven) treatment of platelet-related bleeding disorders. *Blood Coagul Fibrinolysis* 2000; 11(Suppl1):55-68
110. Potapov EV, Pasic M, Bauer M, Hetzer R: Activated Recombinant Factor VII for Control of Diffuse Bleeding after Implantation of Ventricular Assist Device. *Ann Thorac Surg* 2002; 74:2182-2183

111. Raivio P, Suojaranta-Ylinen R, Kuitunen AH: Recombinant Factor VIIa in the Treatment of Postoperative Hemorrhage After Cardiac Surgery. *Ann Thorac Surg* 2005; 80:66-71
112. Roberts HR: Clinical experience with activated factor VII: focus on safety aspects. *Blood Coag Fibrinol* 1998; 9 Suppl1:115-118
113. Roberts HR, Monroe DM, White GC: The use of recombinant factor VII in the treatment of bleeding disorders. *Blood* 2004; 104:3858-3864
114. Rocha H, Hidalgo F, Llorens R, Melero JM, Arroyo JL, Paramo JA: Randomized study of aprotinin and DDAVP to reduce postoperative bleeding after cardiopulmonary bypass surgery. *Circulation* 1994; 90:921-927
115. Romagnoli S, Bevilacqua S, Gelsomino S, Pradella S, Ghilli L: Small-dose recombinant activated factor VII (NovoSeven) in cardiac surgery. *Anesth Analg* 2006; 102:1320-1326
116. Sajdak S, Moszynski R, Opala T: Bleeding from endometrial and vaginal malignant tumors treated with activated recombinant factor VII. *Eur J Gynaecol Oncol* 2002; 23: 325-326
117. Scharrer I: Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency. *Haemophilia* 1999; 5:253-259
118. Scharrer I: Gerinnungsaktive Therapeutika. *Hämostaseologie* 2005; 25:209-212
119. Schmuck S, Ganter MT, Hamiel CR, Zollinger A, Hofer CK: Monitoring the Effects of Factor VIIa Treatment In-Vitro after Severe Hemodilution (Part II-ROTEM):
<http://www.asaabstracts.com/strands/asaabstracts/printAbstract.html>
120. Sellman M, Intonti MA: Reoperations for bleeding after coronary artery bypass procedures during 25 years. *Eur J Cardiothorac Surg* 1997; 11: 521-527
121. Shah BR, Laupacis A, Hux JE, Austin PC: Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review. *J Clin Epidemiol* 2005; 58:550-559
122. Shapiro AD, Gilchrist GS, Hoots WK: Prospective, randomised trial of two doses of rFVIIa in haemophilia patients with inhibitors undergoing surgery. *Thromb Haemost* 1998; 80:773-778
123. Siegel LJ, Gerigk L, Tuettenberg J, Dempfle CE.: Cerebral sinus thrombosis in a trauma patient after recombinant activated factor VII infusion. *Anesthesiology* 2004; 100:441-443
124. Sorensen B, Johansen P, Nielsen GL: Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: Clinical and biochemical aspects. *Blood Coagul Fibrinolysis* 2003; 14:469-477
125. Spahn DR, Tucci MA, Makris M: Is recombinant FVIIa the magic bullet in the treatment of major bleeding? *Br J Anaesth* 2005, 94(5):553-555
126. Stehling LC, American Society of Anesthesiologists Task Force on Blood Component Therapy: practice guidelines for blood component therapy: a report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. *Anesthesiology* 1996; 84:365-368

127. Tokunaga C, Hiramatsu Y, Horigome H, Takahashi-Igari M: Palliative Open Heart Surgery in an Infant with Factor VII Deficiency. *Ann Thorac Surg* 2003; 76:2093-2094
128. Trappe U, Riess H: Pathophysiologische Grundsätze bei Sepsis. *Hämostaseologie* 2005; 25:175-182
129. Unsworth-White MJ, Herriot A, Valencia O, Poloniechi J, et al: Resternotomy for bleeding after cardiac operation: a marker for increased morbidity and mortality. *Ann Thorac Surg* 1995; 59:664
130. Van der Planken MG, Schroyens W, Vertessen F, Michieles JJ, Berneman ZN: Distal deep venous thrombosis in a hemophilia A patient with severe infectious disease, 18 days after recombinant activated factor VII transfusion. *Blood Coagul Fibrinolysis* 2002; 13:367-370
131. Vincent JL, Rossaint R, Riou B, Ozier Y, Zideman D, Spahn DR: Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding – a European perspective. *Crit Care* 2006; 10:R120
132. von Heymann C, Hotz H: Successful treatment of refractory bleeding with recombinant Factor VII after Redo coronary artery bypass grafting. *J Cardiothorac Vasc Anesth* 2002; 16(5): 615-616
133. von Heymann C, Redlich U, Jain U, Kastrup M, Schroeder T: Recombinant activated factor VII for refractory bleeding after cardiac surgery—a retrospective analysis of safety and efficacy. *Crit Care Med* 2005; 33:2241-2246
134. von Heymann, Spies C, Grubitzsch H, Schönfeld H, Sander M, Volk T: Blutungen nach herzchirurgischen Operationen. Die Rolle des rekombinanten Faktors VIIa. *Hämostaseologie* 2006; 26(1):77-87
135. von Heymann C, Ziemer S, Kox WJ, Spies C: Caveat against the use of feiba in combination with recombinant factor VIIa. Letter to the editor. *J Thorac Cardiovasc Surg* 2003; 126:1667-1668
136. Walsham J, Fraser JF, Mullany D, Ziegenfus M, Chinthamuneedi M: The use of recombinant activated factor VII for refractory bleeding post complex cardiothoracic surgery. *Anaesth Intensive Care* 2006; 34:13-20
137. Watts DD, Trask A, Soeken K, Perdue P: Hypothermic Coagulopathy in trauma: effect of varying levels of hypothermia on enzyme speed, platelet function and fibrinolytic activity. *J Trauma* 1998; 44:846-854
138. Welsby IJ, Monroe DM, Lawson JH, Hoffmann M: Recombinant activated factor VII and the anaesthetist. *Anaesthesia* 2005; 60:1203-1212
139. White B, McHale J: Successful use of recombinant FVIIa (NovoSeven®) in the management of intractable post-surgical intra-abdominal haemorrhage. *Br J Haematol*, 1999; 107:677-678
140. Willich SN: Randomisierte kontrollierte Studien. Pragmatische Ansätze erforderlich. *Dtsch Arztebl* 2006; 103(39):A2524-2529
141. Wittenstein B, Ng Cho, Ravn H, Goldman A: Recombinant factor VII for severe bleeding during extracorporeal membrane oxygenation following open heart surgery. *Pediatr Crit Care Med* 2005; 6: 473-476
142. Yende S, Wunderink RG: Effect of clopidogrel on bleeding after coronary artery bypass surgery. *Crit Care Med* 2001; 29(12):2271-2275